NLRP3 and Parkinson disease: NLRP3 inhibitors OLT-1177 and JC-124 were found effective against disease progression in APP-PS1 mice with OLT-1177 also showing efficacy in a Parkinson’s disease mouse model.155,166–168 Given the efficacy of canakinumab and anakinra as blockers of the downstream signaling component IL-1β, it can be hypothesized that NLRP3 blockade is a promising upstream target.